基于细胞形态变化观察 GE11 改性紫杉醇和姜黄素脂质体的抗肿瘤机制

Hailing Tang, Lijuan Li, Baoshan Wang
{"title":"基于细胞形态变化观察 GE11 改性紫杉醇和姜黄素脂质体的抗肿瘤机制","authors":"Hailing Tang, Lijuan Li, Baoshan Wang","doi":"10.1186/s41120-023-00090-9","DOIUrl":null,"url":null,"abstract":"Curcumin and paclitaxel are widely used as anti-tumor hydrophobic model drugs for the designation of smart tumor-targeting nanocarriers and the study of the correlation between structural characteristics of nanoparticles and in vivo therapeutic efficacy. Various signaling pathways on cell growth and proliferation have been comprehensively studied in vitro and in vivo under the action of curcumin and paclitaxel nanoparticles. In this paper, we prepared EGFR-targeted GE11 peptide-modified curcumin and paclitaxel compound liposomes (CUR-PTX@GE11-L). The tumor suppression mechanism of CUR-PTX@GE11-L is observed from the aspects of drug release behavior, changes of cell morphology, liver retention, and tumor-targeting efficiency. We hope it can provide a new vision for the rational construction of smart nanoscale drug delivery system through the observation of cytotoxic effects of CUR-PTX@GE11-L, especially on the cellular morphology change. ","PeriodicalId":453,"journal":{"name":"AAPS Open","volume":"67 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Observation of antitumor mechanism of GE11-modified paclitaxel and curcumin liposomes based on cellular morphology changes\",\"authors\":\"Hailing Tang, Lijuan Li, Baoshan Wang\",\"doi\":\"10.1186/s41120-023-00090-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Curcumin and paclitaxel are widely used as anti-tumor hydrophobic model drugs for the designation of smart tumor-targeting nanocarriers and the study of the correlation between structural characteristics of nanoparticles and in vivo therapeutic efficacy. Various signaling pathways on cell growth and proliferation have been comprehensively studied in vitro and in vivo under the action of curcumin and paclitaxel nanoparticles. In this paper, we prepared EGFR-targeted GE11 peptide-modified curcumin and paclitaxel compound liposomes (CUR-PTX@GE11-L). The tumor suppression mechanism of CUR-PTX@GE11-L is observed from the aspects of drug release behavior, changes of cell morphology, liver retention, and tumor-targeting efficiency. We hope it can provide a new vision for the rational construction of smart nanoscale drug delivery system through the observation of cytotoxic effects of CUR-PTX@GE11-L, especially on the cellular morphology change. \",\"PeriodicalId\":453,\"journal\":{\"name\":\"AAPS Open\",\"volume\":\"67 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AAPS Open\",\"FirstCategoryId\":\"1\",\"ListUrlMain\":\"https://doi.org/10.1186/s41120-023-00090-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AAPS Open","FirstCategoryId":"1","ListUrlMain":"https://doi.org/10.1186/s41120-023-00090-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

姜黄素和紫杉醇被广泛用作抗肿瘤疏水性模型药物,用于指定智能肿瘤靶向纳米载体以及研究纳米颗粒结构特征与体内疗效之间的相关性。在姜黄素和紫杉醇纳米颗粒的作用下,对细胞生长和增殖的各种信号通路进行了全面的体外和体内研究。本文制备了靶向 EGFR 的 GE11 肽修饰姜黄素和紫杉醇复合脂质体(CUR-PTX@GE11-L)。从药物释放行为、细胞形态变化、肝脏滞留和肿瘤靶向效率等方面观察了CUR-PTX@GE11-L的抑瘤机制。通过观察CUR-PTX@GE11-L的细胞毒性作用,特别是细胞形态的变化,希望能为合理构建智能纳米级给药系统提供新的思路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Observation of antitumor mechanism of GE11-modified paclitaxel and curcumin liposomes based on cellular morphology changes
Curcumin and paclitaxel are widely used as anti-tumor hydrophobic model drugs for the designation of smart tumor-targeting nanocarriers and the study of the correlation between structural characteristics of nanoparticles and in vivo therapeutic efficacy. Various signaling pathways on cell growth and proliferation have been comprehensively studied in vitro and in vivo under the action of curcumin and paclitaxel nanoparticles. In this paper, we prepared EGFR-targeted GE11 peptide-modified curcumin and paclitaxel compound liposomes (CUR-PTX@GE11-L). The tumor suppression mechanism of CUR-PTX@GE11-L is observed from the aspects of drug release behavior, changes of cell morphology, liver retention, and tumor-targeting efficiency. We hope it can provide a new vision for the rational construction of smart nanoscale drug delivery system through the observation of cytotoxic effects of CUR-PTX@GE11-L, especially on the cellular morphology change.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Pre-analytical stability of ocrelizumab in serum after delayed centrifugation of whole blood Characterization, stability, and skin application of astaxanthin particulates A controlled vocabulary and taxonomy for the submission of quality attributes for therapeutic proteins An in-silico approach towards multivariate acceptable ranges in biopharmaceutical manufacturing Recent progress of small-molecule of RET inhibitors against Non-small cell lung cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1